BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.

about

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.

Item

http://www.wikidata.org/entity/Q42965600

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.

@en

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.

@nl

type

Item

label

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.

@en

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.

@nl

prefLabel

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.

@en

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.

@nl

P1476

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.

@en

P2093

Claudia D Baldus

http://www.w3.org/2001/XMLSchema#string

Hendrik Nogai

http://www.w3.org/2001/XMLSchema#string

Renate Arnold

http://www.w3.org/2001/XMLSchema#string

P2860

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Overriding imatinib resistance with a novel ABL kinase inhibitor

Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation.

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

Chronic Myelogenous Leukemia, Version 1.2014

Practical management of patients with chronic myeloid leukemia receiving imatinib.

P304

25-28

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4137/BMI.S22279

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 3

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Burmeister

Benjamin Nils Ostendorf

P577

2015-08-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26379418

http://www.w3.org/2001/XMLSchema#string

P932

4554357

http://www.w3.org/2001/XMLSchema#string